2-甲基-2-丙基4-{[3-(三氟甲基)苯基]氨基}-1-哌啶羧酸酯 | 477864-09-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-2-丙基4-{[3-(三氟甲基)苯基]氨基}-1-哌啶羧酸酯
• 中文别名: 1-Boc-4-[(3-三氟甲基苯基)氨基]哌啶
• 英文名称: tert-butyl 4-((3-(trifluoromethyl)phenyl)amino)piperidine-1-carboxylate
• 英文别名: 1,1-dimethylethyl 4-((3-(trifluoromethyl)phenyl)amino)-1-piperidinecarboxylate；1-Boc-4-(3-trifluoromethyl-phenylamino)-piperidine；tert-butyl 4-[3-(trifluoromethyl)anilino]piperidine-1-carboxylate
• CAS: 477864-09-8
• 化学式: C₁₇H₂₃F₃N₂O₂
• 分子量: 344.377
• InChiKey: ZIXSGRNDXGVFRZ-UHFFFAOYSA-N

物化性质

• 沸点：
  409.8±45.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基4-{[3-(三氟甲基)苯基]氨基}-1-哌啶羧酸酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成 N-(4-methylpyridin-2-yl)-4-((3-(trifluoromethyl)phenyl)amino)-piperidine-1-carbothioamide trifluoroacetate
  参考文献：
  名称：

  4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-N-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide (ML267), a Potent Inhibitor of Bacterial Phosphopantetheinyl Transferase That Attenuates Secondary Metabolism and Thwarts Bacterial Growth

  摘要：

  4'-Phosphopantetheinyl transferases (PPTases) catalyze a post-translational modification essential to bacterial cell viability and virulence. We present the discovery and medicinal chemistry optimization of 2-pyridinyl-N-(4-aryl)-piperazine-1-carbothioamides, which exhibit submicromolar inhibition of bacterial Sfp-PPTase with no activity toward the human orthologue. Moreover, compounds within this class possess antibacterial activity in the absence of a rapid cytotoxic response in human cells. An advanced analogue of this series, ML267 (55), was found to attenuate production of an Sfp-PPTase-dependent metabolite when applied to Bacillus subtilis at sublethal doses. Additional testing revealed antibacterial activity against methicillin-resistant Staphylococcus aureus, and chemical genetic studies implicated efflux as a mechanism for resistance in Escherichia coli. Additionally, we highlight the in vitro absorption, distribution, metabolism; and excretion and in vivo pharmacokinetic profiles of compound 55 to further demonstrate the potential utility of this small-molecule inhibitor.

  DOI：

  10.1021/jm401752p
• 作为产物：
  描述：

  间氨基三氟甲苯 、 1-Boc-4-氨基哌啶 在 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以55%的产率得到2-甲基-2-丙基4-{[3-(三氟甲基)苯基]氨基}-1-哌啶羧酸酯
  参考文献：
  名称：

  [EN] SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS
  [FR] DÉRIVÉS DE SPIROALCÈNECARBOXAMIDE ET LEUR UTILISATION COMME MODULATEURS DE RÉCEPTEURS DE CHEMOKINES

  摘要：

  本发明涉及以下式（I）的化合物，这些化合物是趋化因子细胞因子受体2（CCR2）和/或5（CCR5）的拮抗剂，以及其药物组合物和使用方法。

  公开号：

  WO2012130915A1

文献信息

• [EN] ANTHELMINTIC AGENTS AND THEIR USE<br/>[FR] AGENTS ANTHELMINTIQUES ET LEUR UTILISATION
  申请人：INTERVET INT BV

  公开号：WO2010115688A1

  公开（公告）日：2010-10-14

  This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds and salts to make medicaments, and treatments comprising the administration of the compounds and salts to animals in need of the treatments.

  这项发明涉及一般用作驱虫剂或作为制备驱虫剂的中间体的化合物和盐。这项发明还涉及制备这些化合物和盐的方法，包括这些化合物和盐的药物组合物和试剂盒，使用这些化合物和盐制备药物，以及将这些化合物和盐用于需要治疗的动物的治疗方法。
• Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators
  申请人：Ares Trading SA

  公开号：EP2508526A1

  公开（公告）日：2012-10-10

  The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.

  本发明涉及以下式（I）的化合物，这些化合物是趋化因子细胞因子受体2（CCR2）和/或5（CCR5）的拮抗剂，以及其药物组合物和使用方法。
• The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis
  作者：Runfeng Lin、Zheng Zhang、Shengtian Cao、Wen Yang、Yinglin Zuo、Xinye Yang、Jiancun Zhang、Juan Xu、Jing Li、Xiaojun Wang

  DOI：10.1039/d1md00023c

  日期：——

  Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, the development of new drugs to treat IPF is an urgent medical need. In this paper we report the discovery of a series of orally active pyrimidin-4(3H)-one

  特发性肺纤维化 (IPF) 是一种慢性进行性肺病，典型的生存时间在三到五年之间。两种药物吡非尼酮和尼达尼布已被批准用于治疗 IPF，但疗效有限。因此，开发治疗IPF的新药是迫切的医疗需求。在本文中，我们报告了一系列口服活性 pyrimidin-4(3 H )-one 类似物的发现，这些类似物在体外试验中表现出有效的活性。其中，HEC-866 在大鼠 IPF 模型中显示出良好的疗效。由于 HEC-866 还具有良好的口服生物利用度、较长的半衰期和良好的长期安全性，因此被选中进行进一步的临床评估。
• Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer’s disease
  作者：Shoaib Manzoor、Moustafa T. Gabr、Bisma Rasool、Kavita Pal、Nasimul Hoda

  DOI：10.1016/j.bioorg.2021.105354

  日期：2021.11

  have demonstrated remarkable efficiency as potential therapeutics for Alzheimer’s disease (AD). Herein, we reported a new series of deoxyvasicinone analogues as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by 1HNMR, 13CNMR and mass spectrometry

  多靶点配体的开发已证明作为阿尔茨海默病 (AD) 的潜在疗法具有显着的效率。在此，我们报道了一系列新的脱氧血管紧张素类似物作为乙酰胆碱酯酶 (AChE) 和 tau 聚集的双重抑制剂，可作为 AD 的多靶点配体。所有多靶点配体11(aj)和15(ag ) 均经过1 HNMR、13 CNMR 和质谱法设计、合成和验证。筛选了所有合成的化合物11(aj)和15(ag ) 抑制 AChE、BACE1、淀粉样蛋白纤维化、α-syn 聚集和 tau 聚集的能力。所有筛选的化合物都对 BACE-1、A β具有弱抑制作用42和 α-syn 聚合。然而，在 AChE 抑制筛选试验和细胞 tau 聚集筛选中，有几种化合物被鉴定为潜在的命中物。在所有化合物中，11f在单剂量筛选 (10 µM) 时显着抑制 AChE 活性和细胞 tau 寡聚化。此外，11f的半数抑制浓度 (IC 50 ) 值分别为 0.91 ±
• BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE
  申请人：Johnson Christopher Norbert

  公开号：US20090054456A1

  公开（公告）日：2009-02-26

  The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.

  本发明涉及新型苄基哌嗪衍生物，如公式(I)化合物，其具有作为GPR38受体激动剂的活性，以及在治疗胃肠道疾病中使用这些化合物或其制剂的药物组合物。